Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
can decrease » a decrease (Expand Search), nn decrease (Expand Search), gain decreased (Expand Search)
_ largest » _ large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
can decrease » a decrease (Expand Search), nn decrease (Expand Search), gain decreased (Expand Search)
_ largest » _ large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
-
1
-
2
-
3
-
4
-
5
ECoG timescales decrease during spatial attention.
Published 2025“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
Repetitive stress induces a decrease in sound-evoked activity.
Published 2025“…<p>(a) Left: noise-evoked activity rates at different noise intensities for chronically tracked PPys cells in baseline and repeated stress conditions (<i>N</i> = 5 mice, <i>n</i> = 285 neurons, mean ± SE). Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 185.6, <i>p</i> = 4.8 × 10<sup>−42</sup>, condition: intensity interaction F = 10.37, <i>p</i> = 9.3 × 10<sup>−21</sup>, nested ANOVA (mouse nested within session), condition F = 174, <i>p</i> = 1.5 × 10<sup>−39</sup>, condition: intensity interaction F = 12.7, <i>p</i> = 2 × 10<sup>−26</sup>, post hoc for each level baseline versus repetitive stress <i>p</i> < 0.01 for all levels above 50 dB, all Bonferroni corrected). …”
-
14
-
15
-
16
-
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
18
-
19
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
20
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: